J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92.

Buyse M., Loi S., van’t Veer L., Viale G., Delorenzi M., Glas A.M., d’Assignies M.S., Bergh J., Lidereau R., Ellis P., Harris A., Bogaerts J., Therasse P., Floore A., Amakrane M., Piette F., Rutgers E., Sotiriou C., Cardoso F., Piccart M.J.; TRANSBIG Consortium.

The 70-gene signature outperformed the clinicopathologic risk assessment in predicting all endpoints. For time to distant metastases, the gene signature yielded HR = 2.32.

Read more: Buyse et al_2006_Journal of the National Cancer Institute_Validation and Clinical Utility